Biocytogen is excited to attend LSX Congress USA 2026 from September 23rd–24th in Boston, MA. As part of Biotech Week Boston, the congress will bring together biotech executives, pharmaceutical leaders, and investors to explore investment and partnership opportunities. Come meet our team and join us in learning about advanced, innovative drug discovery and development.
What is the LSX Congress USA 2026?
LSX Congress USA is a leading life science partnering and investment event built to connect biotech companies with investors and partners to support their next stage of growth. The two-day event features panels, interactive discussions, company showcases, and case studies. Attendees can also take part in qualified 1:1 partnering meetings, speed networking, networking breaks, and evening receptions, creating opportunities to establish new relationships, exchange industry insights, and explore potential collaborations.
Event Overview
Date: September 23rd - 24th, 2026
Venue: Hynes Convention Center, 900 Boylston St, Boston, MA 02115
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
